title: Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
authors.forename: Weerawat
authors.initials: W
authors.lastname: Manosuthi
authors.forename: Aroon
authors.initials: A
authors.lastname: Lueangniyomkul
authors.forename: Wiroj
authors.initials: W
authors.lastname: Mankatitham
authors.forename: Sukanya
authors.initials: S
authors.lastname: Chimsuntorn
authors.forename: Preecha
authors.initials: P
authors.lastname: Tantanathip
authors.forename: Supeda
authors.initials: S
authors.lastname: Thongyen
authors.forename: Busakorn
authors.initials: B
authors.lastname: Suntisuklappon
authors.forename: Samruay
authors.initials: S
authors.lastname: Nilkamhang
authors.forename: Somnuek
authors.initials: S
authors.lastname: Sungkanuparph
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D018119:Stavudine / Q000008:administration & dosage* / Q000009:adverse effects; D000068698:Tenofovir; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D019259:Lamivudine; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine